The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | ALCANZA: brentuximab vedotin for CTCL
Chalid Assaf, MD, PhD, Helios Klinikum Krefeld, Krefeld, German, shares an update on the Phase III ALCANZA trial (NCT01578499) of brentuximab vedotin for the treatment of CD20-positive cutaneous T-cell lymphoma (CTCL) and comments on its significance in the field. Dr Assaf reports that brentuximab vedotin achieved a high response rate of over 60% and a progression-free survival of around 60.7 months, in comparison to 3.5-4 months in the methotrexate and bexarotene arms. Dr Assaf also highlights significant benefits in quality of life for patients who received brentuximab vedotin and gives an overview of the safety profile. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
